Compare Crispr Therapeutics AG (CRSP) vs Innovative Industrial Properties Inc (IIPR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Innovative Industrial Properties Inc — how do they compare? Crispr Therapeutics AG trades at $51.28 (market cap $4.97B), while Innovative Industrial Properties Inc trades at $63.64 (market cap $1.85B). The key difference: Crispr Therapeutics AG is far larger — about 2.7× Innovative Industrial Properties Inc's market cap, and Innovative Industrial Properties Inc pays a 11.93% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | IIPR | |
|---|---|---|
Market Cap | $4.97B | $1.85B |
Sector | Health | Real Estate |
52-Week High | $76.78 | $64.44 |
52-Week Low | $44.34 | $44.58 |
Enterprise Value | $3.32B | $2.23B |
Dividend Yield | — | 11.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
IIPR trades at $63.78, down 1.02% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported mixed quarterly earnings, beating in Q4 2025 but missing in Q1 2026, with revenue declining to $266M in 2025. Recent news highlights successful debt management, including repaying $282M in senior notes and issuing new debt, while cannabis rescheduling progress offers regulatory tailwinds.
The outlook for IIPR balances a high dividend yield and improved balance sheet against revenue declines and tenant risks. Investment opportunities include potential re-rating from regulatory changes and stable cash flows, but risks involve sector volatility and earnings inconsistency. Analyst sentiment is mixed with a Hold consensus, reflecting cautious optimism amid fundamental challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Innovative Industrial Properties Inc
Innovative Industrial Properties Inc is a real estate investment trust engaged in the acquisition, ownership, and management of specialized industrial properties leased to state-licensed operators for their regulated medical-use cannabis facilities. It conducts its business through a traditional umbrella partnership real estate investment trust, or UPREIT structure, in which properties are owned by Operating Partnership, directly or through subsidiaries. Its property portfolio is spread across the United States.
Read more on IIPR →
